208 related articles for article (PubMed ID: 25693879)
21. Evaluation of the Incremental Healthcare Economic Burden of Patients with Atrial Fibrillation Treated with Direct-Acting Oral Anticoagulants and Hospitalized for Major Bleeds in the USA.
Deitelzweig SB; Lovelace B; Christoph M; Lingohr-Smith M; Lin J; Fermann GJ
Adv Ther; 2020 Sep; 37(9):3942-3953. PubMed ID: 32699994
[TBL] [Abstract][Full Text] [Related]
22. Transient atrial fibrillation complicating acute inferior myocardial infarction: implications for future risk of ischemic stroke.
Siu CW; Jim MH; Ho HH; Miu R; Lee SW; Lau CP; Tse HF
Chest; 2007 Jul; 132(1):44-9. PubMed ID: 17400657
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.
Lee S; Anglade MW; Meng J; Hagstrom K; Kluger J; Coleman CI
Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):472-9. PubMed ID: 22740012
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting.
Wu B; Kun L; Liu X; He B
Cardiovasc Drugs Ther; 2014 Feb; 28(1):87-98. PubMed ID: 24048510
[TBL] [Abstract][Full Text] [Related]
25. Costs of major intracranial, gastrointestinal and other bleeding events in patients with atrial fibrillation - a nationwide cohort study.
Jakobsen M; Kolodziejczyk C; Klausen Fredslund E; Poulsen PB; Dybro L; Paaske Johnsen S
BMC Health Serv Res; 2017 Jun; 17(1):398. PubMed ID: 28606079
[TBL] [Abstract][Full Text] [Related]
26. Implementing Guidelines: The Cost and Clinical Impact of Anticoagulants in the UK Atrial Fibrillation Population.
Shields GE; Bates AE; Chapman AM
Appl Health Econ Health Policy; 2015 Oct; 13(5):543-51. PubMed ID: 26077910
[TBL] [Abstract][Full Text] [Related]
27. Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation.
Singh SM; Wijeysundera HC
Curr Cardiol Rep; 2015 Aug; 17(8):61. PubMed ID: 26081245
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation.
Lanitis T; Kongnakorn T; Jacobson L; De Geer A
Thromb Res; 2014 Aug; 134(2):278-87. PubMed ID: 24935675
[TBL] [Abstract][Full Text] [Related]
30. Cost-Effectiveness of High-Dose Edoxaban Compared with Adjusted-Dose Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation Patients.
Nguyen E; Egri F; Mearns ES; White CM; Coleman CI
Pharmacotherapy; 2016 May; 36(5):488-95. PubMed ID: 27015873
[TBL] [Abstract][Full Text] [Related]
31. Annual costs attributed to atrial fibrillation management: cross-sectional study of primary healthcare electronic records.
Casajuana M; Giner-Soriano M; Roso-Llorach A; Vedia C; Violan C; Morros R
Eur J Health Econ; 2018 Nov; 19(8):1129-1136. PubMed ID: 29464418
[TBL] [Abstract][Full Text] [Related]
32. Burden of atrial fibrillation: a retrospective review of patients presenting to acute medical services.
Jolliffe E; Fu V; Lanford J; Weatherall M; Rosemergy I
Intern Med J; 2016 Oct; 46(10):1166-1171. PubMed ID: 27501863
[TBL] [Abstract][Full Text] [Related]
33. Estimated medical cost reductions associated with apixaban in real-world patients with non-valvular atrial fibrillation.
Amin A; Stokes M; Wu N; Gatt E; Makenbaeva D; Wiederkehr D; Boulanger L
J Med Econ; 2013 Oct; 16(10):1193-202. PubMed ID: 23883416
[TBL] [Abstract][Full Text] [Related]
34. Role of new drugs for management of atrial fibrillation.
Hollands JM; Gowan M; Riney JN; Deal EN; Kates AM
Ann Pharmacother; 2012 Dec; 46(12):1656-70. PubMed ID: 23249869
[TBL] [Abstract][Full Text] [Related]
35. Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective.
Athanasakis K; Boubouchairopoulou N; Karampli E; Tarantilis F; Savvari P; Bilitou A; Kyriopoulos J
Am J Cardiovasc Drugs; 2017 Apr; 17(2):123-133. PubMed ID: 27882517
[TBL] [Abstract][Full Text] [Related]
36. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
J Med Econ; 2013 Sep; 16(9):1163-8. PubMed ID: 23869941
[TBL] [Abstract][Full Text] [Related]
37. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
Reddy P; Giugliano RP
J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
[TBL] [Abstract][Full Text] [Related]
38. Retrospective study of total healthcare costs associated with chronic nonvalvular atrial fibrillation and the occurrence of a first transient ischemic attack, stroke or major bleed.
Boccuzzi SJ; Martin J; Stephenson J; Kreilick C; Fernandes J; Beaulieu J; Hauch O; Kim J
Curr Med Res Opin; 2009 Dec; 25(12):2853-64. PubMed ID: 19916729
[TBL] [Abstract][Full Text] [Related]
39. Resource utilization and outcomes in patients with atrial fibrillation: a case control study.
Boggon R; Lip GY; Gallagher AM; van Staa TP
Appl Health Econ Health Policy; 2012 Jul; 10(4):249-59. PubMed ID: 22540235
[TBL] [Abstract][Full Text] [Related]
40. Anticoagulation therapy in patients with stroke and atrial fibrillation: a registry-based study of acute stroke care in Surrey, UK.
Han TS; Fry CH; Fluck D; Affley B; Gulli G; Barrett C; Kakar P; Patel T; Sharma S; Sharma P
BMJ Open; 2018 Jul; 8(7):e022558. PubMed ID: 29997144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
